Paclitaxel incorporated exosomes derived from glioblastoma cells: comparative study of two loading techniques.
Exosome
Glioblastoma cell line
Paclitaxel
Sonication; loading
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
19
01
2019
accepted:
11
06
2019
pubmed:
19
7
2019
medline:
10
4
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Exosomes are natural nanoparticles that are involved in intercellular communication via transferring molecular information between cells. Recently, exosomes have been considered for exploitation as novel drug delivery systems due to their specific properties for carrying specific molecules and surface proteins. In this study, U-87 cell derived exosomes have been investigated for delivery of a potent chemotherapeutic agent, paclitaxel (PTX). Two methods of loading were utilized to incorporate PTX in exosomes and the exosomes pharmaceutical and cytotoxic characterizations were determined. The drug loaded and empty exosomes were found to have particle size of 50-100 nm and zeta potential of ≈ - 20 mV. Loading capacity of 7.4 ng and 9.2 ng PTX into 1 μg of exosome total protein were also measured for incubation and sonication methods, respectively. Incorporation of PTX into exosomes significantly increased its cytotoxicity against U-87 cell line (59.92% cell viability) while it was found that the empty exosomes exhibited cell viability of 91.98%. Loading method could affect the loading capacity of exosomes and their encapsulated chemotherapeutic molecule showed higher cytotoxicity into exosomes. These results promise exosomes as appropriate drug delivery system for glioblastoma multiform (GBM) treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Exosomes are natural nanoparticles that are involved in intercellular communication via transferring molecular information between cells. Recently, exosomes have been considered for exploitation as novel drug delivery systems due to their specific properties for carrying specific molecules and surface proteins.
METHODS
METHODS
In this study, U-87 cell derived exosomes have been investigated for delivery of a potent chemotherapeutic agent, paclitaxel (PTX). Two methods of loading were utilized to incorporate PTX in exosomes and the exosomes pharmaceutical and cytotoxic characterizations were determined.
RESULTS
RESULTS
The drug loaded and empty exosomes were found to have particle size of 50-100 nm and zeta potential of ≈ - 20 mV. Loading capacity of 7.4 ng and 9.2 ng PTX into 1 μg of exosome total protein were also measured for incubation and sonication methods, respectively. Incorporation of PTX into exosomes significantly increased its cytotoxicity against U-87 cell line (59.92% cell viability) while it was found that the empty exosomes exhibited cell viability of 91.98%.
CONCLUSIONS
CONCLUSIONS
Loading method could affect the loading capacity of exosomes and their encapsulated chemotherapeutic molecule showed higher cytotoxicity into exosomes. These results promise exosomes as appropriate drug delivery system for glioblastoma multiform (GBM) treatment.
Identifiants
pubmed: 31317441
doi: 10.1007/s40199-019-00280-5
pii: 10.1007/s40199-019-00280-5
pmc: PMC6895332
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Drug Carriers
0
Paclitaxel
P88XT4IS4D
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-539Subventions
Organisme : Kerman University of Medical Sciences
ID : grant No. 95000430
Références
J Cell Mol Med. 2018 Mar;22(3):2001-2006
pubmed: 29377463
Int J Pharm. 2007 Jan 10;328(2):130-41
pubmed: 16997517
J Extracell Vesicles. 2016 Nov 17;5:32570
pubmed: 27863537
J Diabetes Res. 2016;2016:5741518
pubmed: 28105442
J Extracell Vesicles. 2015 Mar 26;4:27269
pubmed: 25819214
Daru. 2015 Apr 23;23:28
pubmed: 25903677
Int J Pharm. 2017 Apr 15;521(1-2):167-175
pubmed: 28216464
J Control Release. 2015 Jun 10;207:18-30
pubmed: 25836593
Nanomedicine. 2017 Jul;13(5):1627-1636
pubmed: 28300659
Int J Nanomedicine. 2018 Aug 08;13:4509-4521
pubmed: 30127603
Anal Biochem. 2014 Mar 1;448:41-9
pubmed: 24333249
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
Adv Healthc Mater. 2015 Jun 3;4(8):1236-45
pubmed: 25761648
Biochim Biophys Acta. 2014 Aug;1846(1):75-87
pubmed: 24747178
Eur J Pharm Biopharm. 2014 Nov;88(3):746-58
pubmed: 25445304
Biomaterials. 2012 Nov;33(32):8167-76
pubmed: 22889488
Sci Rep. 2015 Jan 06;5:7639
pubmed: 25559219
Acta Pharm Sin B. 2018 Jan;8(1):85-96
pubmed: 29872625
Mol Ther. 2010 Sep;18(9):1606-14
pubmed: 20571541
ACS Nano. 2013 Sep 24;7(9):7698-710
pubmed: 24004438
J Control Release. 2015 Dec 28;220(Pt B):727-37
pubmed: 26390807
Nanomedicine. 2016 Apr;12(3):655-664
pubmed: 26586551
Colloids Surf B Biointerfaces. 2011 Oct 1;87(1):146-50
pubmed: 21640565
J Control Release. 2018 Jul 10;281:42-57
pubmed: 29753958
Acta Pharmacol Sin. 2017 Jun;38(6):754-763
pubmed: 28392567
J Control Release. 2015 Dec 10;219:396-405
pubmed: 26241750
Biomaterials. 2014 Feb;35(7):2383-90
pubmed: 24345736
Nanomedicine (Lond). 2013 Sep;8(9):1443-58
pubmed: 23384702
PLoS One. 2013 Sep 19;8(9):e75054
pubmed: 24069378
J Clin Neurosci. 2017 Jan;35:13-23
pubmed: 27771233
Cancer Lett. 2016 Feb 1;371(1):48-61
pubmed: 26604130
Pharm Res. 2015 Jun;32(6):2003-14
pubmed: 25609010
PLoS One. 2017 Jan 23;12(1):e0170628
pubmed: 28114422
Cell Mol Neurobiol. 2016 Apr;36(3):343-52
pubmed: 26983831